Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie Hubbard

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
BMJ Open|July 12, 2023
Identifying efficient linkage strategies for men (IDEaL): a study protocol for an individually randomised control trialKathryn Dovel, Kelvin Balakasi, Julie Hubbard, et al.
AIDS (London, England)|November 26, 2019
Eligibility for differentiated models of HIV treatment service delivery: an estimate from Malawi and ZambiaRisa M Hoffman, Kelvin Balakasi, Ashley R Bardon, et al.
The Lancet. Global Health|April 18, 2021
Multimonth dispensing of up to 6 months of antiretroviral therapy in Malawi and Zambia (INTERVAL): a cluster-randomised, non-blinded, non-inferiority trialRisa M Hoffman, Crispin Moyo, Kelvin T Balakasi, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
BMJ Open|July 12, 2023
Identifying efficient linkage strategies for men (IDEaL): a study protocol for an individually randomised control trialKathryn Dovel, Kelvin Balakasi, Julie Hubbard, et al.
AIDS (London, England)|November 26, 2019
Eligibility for differentiated models of HIV treatment service delivery: an estimate from Malawi and ZambiaRisa M Hoffman, Kelvin Balakasi, Ashley R Bardon, et al.
The Lancet. Global Health|April 18, 2021
Multimonth dispensing of up to 6 months of antiretroviral therapy in Malawi and Zambia (INTERVAL): a cluster-randomised, non-blinded, non-inferiority trialRisa M Hoffman, Crispin Moyo, Kelvin T Balakasi, et al.
Pageof 3